CAS: 1981-38-0; 2-Phenylanthracene

上下游产品

CAS号7321-27-9 2-溴蒽 | CAS号98-80-6 苯硼酸 | CAS号6485-97-8 2-苯基蒽醌 | CAS号17135-78-3 2-氯蒽 | CAS号573-57-9 1,4-环氧-1,4-二氢萘 | CAS号5910-32-7 1,4-dihydro-Ant... | CAS号176236-88-7 2,3-环氧-1,2,3,4-四水蒽 | CAS号83143-01-5 9,10-epoxy-1,4,... | CAS号10566-32-2 2-iodoanthracen... | CAS号117-79-3 2-氨基蒽醌

📜氯代环己烷置于platinum On Activated Charcoal,铜体系中,化学反应生成2-苯基蒽
参考文献:Sidorova,N.G.; Saidova,F.M.,Journal Of General Chemistry Of The Ussr,1961,Vol. 31,P. 1883-1885
标题:Sidorova,N.G.; Saidova,F.M.,Journal Of General Chemistry Of The Ussr,1961,Vol. 31,P. 1883-1885

专利信息

专利号:WO-2006079916-A1
优先权日:2005-01-26
标 题 :Thieno [2,3-d] pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
发明人：ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; RAHMAN HAYAT; SCHWEITZER BARBARA ANN; TENBRINK RUTH ELIZABETH
权利人:PHARMACIA & UPJOHN CO LLC; ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; RAHMAN HAYAT; SCHWEITZER BARBARA ANN; TENBRINK RUTH ELIZABETH
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I): wherein A1, A2, A3, A4, A5, A6, A7, A8, X4, X6, R2, R4, R5, and R6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-11136286-B2
优先权日:2017-01-27
标题:Diamine compound, and polyimide compound and molded product using the same
发明人：GOSHIMA TOSHIYUKI; SOE WIN MAW
权利人:WINGO TECH CO LTD
摘要:[Problems to be solved] The present invention provides a novel diamine compound which allows for the synthesis of a polyimide compound having a high solubility in an organic solvent and a high melt moldability.[Solution] The diamine compound according to the present invention is characterized by being represented by the following general formula (1):(whereinR1 to R8 are each independently selected from the group consisting of a hydrogen atom, a fluorine atom, a substituted or unsubstituted alkyl group, and a substituted or unsubstituted aromatic group; and at least one of R1 to R8 is a substituted or unsubstituted aromatic group).

专利号:WO-03051298-A2
优先权日:2001-12-14
标 题:Preparation of intermediates useful in the synthesis of antiviral nucleosides

专利号:US-2008176857-A1
优先权日:2005-03-25
标题 :4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors
发明人：ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; TENBRINK RUTH ELIZABETH
权利人:ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; TENBRINK RUTH ELIZABETH
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: n n n n n n n n n n wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2 , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-2008200475-A1
优先权日:2005-03-28
标题:4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors
发明人：ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; TENBRINK RUTH ELIZABETH
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: (I) wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , R 2a , R x , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-2008194590-A1
优先权日:2005-03-28
标 题:4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors
发明人：ENNIS MICHAEL DALTON; KORTUM STEVEN WADE; TENBRINK RUTH ELIZABETH
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , A 8 , X 4 , X 6 , X 2k , R 2l , R 4 , R 5 , and R 6 are as defined in the detailed description of the invention. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.